Q4 2025 Management View CEO Punit Dhillon outlined recent progress for nimacimab, highlighting the transition from promising early signals to a robust development case. Dhillon stated, "CBeyond ...

I had thought problem sets were only for STEM courses, with the notable exception of economics. But despite my initial ...